- Details
- Description
-
Packaging Size63c/bottle
-
Strength25mg
-
CompositonInfigratinib
-
TreatmentCholangiocarcinoma (bile duct cancer)
-
FormCapsule
-
BrandLuciNfig 25
-
Quantity Unit25mg*63c/box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Infigratinib
Infigratinib is a fibroblast growth factor receptor (FGFR) kinase inhibitor used in the treatment of certain types of cholangiocarcinoma (bile duct cancer) and also under investigation for achondroplasia.
Clinical Studies
The efficacy of Infigratinib (Brand name: Truseltiq) was based on a single-arm Phase 2 study which included 108 patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. Ninety-nine percent of patients had metastatic (Stage IV) disease at the time of study entry.
These 108 adult patients with advanced/metastatic CCA received infigratinib 125 mg orally for 21 days of each 28-day cycle until unacceptable toxicity or disease progression. All patients received prophylaxis with the oral phosphate binder sevelamer. Truseltiq achieved a 23% objective response rate (ORR) and a median duration of response (DOR) of 5.0 months.
